Partnerships

---

 A Contract Research Organization (CRO) based in Hyderabad, India, specializing in end-to-end clinical research services. Noah Therapeutics offers bioavailability and bioequivalence (BA/BE) studies, Phase I–IV clinical trials, pharmacokinetics, and bioanalytical testing. The company operates a state-of-the-art 84-bed clinical facility and a 4,000 sq. ft. bioanalytical lab equipped with LC-MS/MS technology. Adhering to ICH-GCP guidelines and regulatory standards, Noah Therapeutics provides high-quality, compliant, and cost-effective solutions to the pharmaceutical, biotechnology, and medical device industries. 

A clinical-stage biopharmaceutical company headquartered in Fremont, California, specializing in the development of innovative therapies derived from botanical sources. ABVC BioPharma's pipeline includes drug candidates targeting major depressive disorder, attention deficit hyperactivity disorder, triple-negative breast cancer, myelodysplastic syndromes, metastatic pancreatic cancer, and retinal detachment. The company operates an asset-light model by in-licensing promising technologies from global research institutions and advancing them through clinical trials. ABVC BioPharma aims to address unmet medical needs and improve patient outcomes through its scientifically validated and cost-effective therapeutic solutions 

 A world-leading medical university based in Stockholm, Sweden, founded in 1810 and internationally recognized for its excellence in research and education. Karolinska Institutet plays a central role in advancing global health and is uniquely responsible for selecting the Nobel laureates in Physiology or Medicine. The university offers a broad range of programs in medicine and health sciences, with a strong focus on translational research. Through close collaboration with hospitals, academic institutions, and industry partners, Karolinska aims to improve human health by turning scientific discoveries into real-world healthcare solutions. 

A globally active multi-family office headquartered in Zollikon, Switzerland. Founded by Dr. René Eichenberger and Rob-Roy Roedel, NVA blends institutional expertise, entrepreneurial spirit, and hands-on management to support people, companies, and communities through entrepreneurship. Specializing in venture capital and private equity investments, it focuses primarily on digital and technology sectors. Its mission is to act as a global company builder, unlocking the full value potential of investments to drive sustainable growth and positive impact worldwide. 

Founded in 2021, Nordic Range AB is a specialist wholesaler dedicated to working closely with doctors and clinics across Scandinavia. The company focuses on sourcing and supplying unlicensed medicines to meet specific patient needs that cannot be fulfilled by licensed alternatives. Nordic Range AB ensures compliance with regulatory requirements while providing reliable access to essential medications. By collaborating directly with healthcare professionals, the company supports personalized patient care and helps bridge gaps in pharmaceutical availability throughout the region. 

Founded in 2006, CTSC has held a Swiss Medic License for pharmaceutical distribution since its establishment. The company’s team possesses over 50 years of combined expertise in pharmaceutical wholesaling throughout Europe, ensuring deep industry knowledge and reliable service. CTSC focuses on sourcing and distributing bulk and intermediate pharmaceuticals specifically for magistral preparations and small-scale manufacturing. Serving clients both within Switzerland and internationally, CTSC is committed to providing high-quality products and dependable supply chain solutions. Their extensive experience and regulatory compliance make them a trusted partner in the pharmaceutical distribution sector. 

 A late-stage clinical company focused on developing innovative therapies to prevent acute organ injury, particularly acute kidney injury (AKI). Arch is advancing two leading drug candidates: LSALT peptide, a Phase II-stage inhibitor targeting the dipeptidase‑1 (DPEP1) inflammation pathway, and cilastatin, a repurposed therapeutic with potential to mitigate toxin-induced AKI in lungs, liver, and kidneys Through strong collaborations with research institutions and a strategic platform approach, Arch aims to address critical unmet medical needs. With global trials underway, the company seeks to deliver life-saving treatments that improve outcomes for patients at risk of inflammation-driven organ damage 

 A Nashville-based technology company harnessing AI and blockchain to transform healthcare data into actionable insights. Its platform streamlines complex workflows including billing, appointment scheduling, medical coding, and clinical research enhancing accuracy and efficiency. Serving insurers, providers, data clearinghouses, and life and disability insurers, Health Reasoning empowers stakeholders across the healthcare ecosystem. With a focus on innovation, the company extracts intelligence from vast unstructured data sets to improve patient outcomes and operational performance. Led by a team of healthcare and technology experts, Health Reasoning is dedicated to reshaping healthcare through intelligent data solutions. 

Celfex AB is a subsidiary of MHG Management GmbH – as Swiss based pharma company.
Celfex AB has a focus on the development of Atopic Dermatitis IP which has been sub-licensed from MHG Management GmbH.
Celfex AB has organized itself in a way which will drive cost effective and accelerated development of our licensed intellectual property. We collaborate with our parent company, with CRO partners and advisors to manage overhead risk and leverage best practices.
 

A biotechnology company based in Boston, Massachusetts, specializing in innovative intranasal therapies. Its flagship product, Profi Nasal Spray, is a drug-free solution designed to proactively cleanse nasal passages of airborne contaminants, offering up to eight hours of protection. Developed from research at Brigham and Women’s Hospital, Profi forms a gel-like barrier that captures and neutralizes pathogens such as influenza, SARS-CoV-2, and RSV. Recognized as one of the World’s Most Innovative Companies in 2025, Akita is redefining health with cutting-edge nasal sprays built for prevention, precision, and lasting impact.